Immunosuppressant Monitoring-Performance of the First Mass Spectrometry-Based Automated Clinical Analyzer Cascadion

被引:1
|
作者
Grote-Koska, Denis [1 ]
Czajkowski, Stefan [1 ]
Staaden, Antje [1 ]
Brand, Korbinian [1 ]
机构
[1] Hannover Med Sch, Inst Clin Chem, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
immunosuppressants; LC-MS; MS; automated analyzer; CYCLOSPORINE-A; TACROLIMUS; ASSAY;
D O I
10.1097/FTD.0000000000001051
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background:Automatic analyzers simplify processes and may help improve standardization. The first automated analyzer based on mass spectrometry is available and offers a panel for monitoring cyclosporin A, tacrolimus, sirolimus, and everolimus. Method comparisons and evaluation tests are presented to verify the capability of the Cascadion system for use in a clinical laboratory.Methods:Sample preparation and measurements were performed using the Cascadion clinical analyzer. More than 1000 measurement values of patient samples were compared with an in vitro diagnostic-certified assay run on a liquid chromatography tandem mass spectrometry instrument. Precision and accuracy were determined using commercial quality control and external quality assessment (EQA) samples.Results:A good correlation between the 2 instruments was observed (Pearson correlation r = 0.956-0.996). Deming regression revealed 95% confidence intervals of slopes and intercepts covering the values 1 and 0, for sirolimus and everolimus, respectively, indicating equivalence of both measuring systems. However, for cyclosporin A, a bias was observed and confirmed using a Bland-Altman plot (-9.1%). Measurement repeatability and intermediate measurement precision were appropriate showing coefficients of variation of 0.9%-6.1% and 2.0%-5.3%, respectively. Accuracy according to internal quality controls was 85%-111% and 81%-100% in the EQA samples of Reference Institute of Bioanalytics and Laboratory of the Government Chemist, respectively. High robustness was found with regard to the linearity of the calibration lines (linear regression coefficient r(2) > 0.99). Carryover was negligible (0.1%).Conclusions:The Cascadion automatic analyzer produced convincing results in the measurement of patient, control, and EQA samples. The throughput was sufficient for routine use. Overall, it can be used as an alternative to open liquid chromatography tandem mass spectrometry instruments for immunosuppressant monitoring, simplifying processes without the need for specially trained personnel.
引用
收藏
页码:14 / 19
页数:6
相关论文
共 50 条
  • [41] Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm
    Metzger, Jochen
    Luppa, Peter B.
    Good, David M.
    Mischak, Harald
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2009, 46 (03) : 129 - 152
  • [42] Therapeutic drug monitoring of immunosuppressant drugs by high-performance liquid chromatography-mass spectrometry
    Taylor, PJ
    THERAPEUTIC DRUG MONITORING, 2004, 26 (02) : 215 - 219
  • [43] Performance characteristics of the new fully automated Lc-Ms/Ms total vitamin D assay on the thermo scientific cascadion Sm clinical analyzer
    Gutierrez, B.
    CLINICA CHIMICA ACTA, 2019, 493 : S163 - S164
  • [44] Mass spectrometry-based characterization of histones in clinical samples: applications, progresses, and challenges
    Noberini, Roberta
    Robusti, Giulia
    Bonaldi, Tiziana
    FEBS JOURNAL, 2022, 289 (05) : 1191 - 1213
  • [45] Mass spectrometry-based proteomics: Current status and potential use in clinical chemistry
    Binz, PA
    Hochstrasser, DF
    Appel, RD
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2003, 41 (12) : 1540 - 1551
  • [46] Advancements in Mass Spectrometry-Based Targeted Metabolomics and Lipidomics: Implications for Clinical Research
    Anh, Nguyen Ky
    Thu, Nguyen Quang
    Tien, Nguyen Tran Nam
    Long, Nguyen Phuoc
    Nguyen, Huy Truong
    MOLECULES, 2024, 29 (24):
  • [47] Mass Spectrometry-Based Approaches for Clinical Biomarker Discovery in Traumatic Brain Injury
    Creech, Matthew
    Carvalho, Lindsey
    McCoy, Heather
    Jacobs, Jon
    Hinson, H. E.
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2022, 24 (12) : 605 - 618
  • [48] Is the automated Elecsys tacrolimus assay on the Roche cobas e 602 analyzer an acceptable replacement for a liquid chromatography-tandem mass spectrometry-based assay?
    Kanegusuku, Anastasia Gant
    Yeo, Kiang-Teck J.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2024, 161 (01) : 97 - 106
  • [49] Metabolomics: a review of liquid chromatography mass spectrometry-based methods and clinical applications
    Dogan, Halef Okan
    TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, 2024, 49 (01): : 1 - 14
  • [50] Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics
    Chen, Yi-Ting
    Tsai, Cheng-Han
    Chen, Chien-Lun
    Yu, Jau-Song
    Chang, Ying-Hsu
    JOURNAL OF FOOD AND DRUG ANALYSIS, 2019, 27 (02) : 387 - 403